| Luxendo–SEVERAL: investment, 201701 financing round Series A extension €2m bringing total to €8m co-led by LSP + EMBL Ventures + EMBLEM |
2017-01-12 |
| Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck |
2017-01-12 |
| Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs |
2017-01-10 |
| Amgen–Immatics: cancer immunotherapy, 201701– strategic collab $30m upfront + $500m milestones + royalties combining Xpresident + BiTE technologies |
2017-01-09 |
| Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m |
2017-01-09 |
| Epidarex Capital–Lilly: investment, 201701 existent one of several investors in Epidarex is Eli Lilly |
2017-01-09 |
| Eternygen–Berlin (govt): investment, 201701 financing round Series A totalling €8m incl co-investor VC Fonds Technologie managed by IBB |
2017-01-09 |
| Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital |
2017-01-09 |
| Eternygen–Evotec: investment, 201701 financing round Series A totalling €8m incl co-investor Evotec AG |
2017-01-09 |
| Eternygen–MC Services: public relations, 201701 service existent by MC Services AG |
2017-01-09 |
| Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al |
2017-01-09 |
| Merck (DE)–Univ Texas: oncology, 201701–201912 strategic collab using MD Anderson’s APOLLO platform for cancer drug development |
2017-01-09 |
| OmicSoft–Qiagen: investment, 201701 acquisition €na of OmicSoft by Qiagen |
2017-01-09 |
| Servier–McDermott Will & Emery: legal services, 201701 advisor immuno-oncology co-developm agreem of Servier with Pieris Pharmaceuticals |
2017-01-09 |
| Anokion–Celgene: investment, 201701 acquisition of equity interest by Celgene as part of research collab research plus excl option to acquire Anokion |
2017-01-08 |
| Celgene–Anokion: immune tolerance inducing drugs, 201701– collab research $45m upfront + $10m milestones + equity share + right to acquire Anokion |
2017-01-08 |
| HepaRegenix–Boehringer: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–Germany (govt): investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–High-Tech Gründerfonds: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–MC Services: public relations, 201701 service existent by MC Services AG |
2017-01-05 |
| HepaRegenix–Novo Group: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–SEVERAL: investment, 201701 financing round Series A €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| Merck (US)–Valneva: cell line, 201701– research license €na for development of new vaccines using EB66 technology to MSD Animal Health |
2017-01-05 |
| Servier–Pieris: cancer immunotherapy, 201701– collab €30m upfront + milestones to develop bi-specific ABs using Anticalin technology incl PRS-322 |
2017-01-05 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| Affimed–Univ Texas: cancer immunotherapy, 201701– collab clinical + commerc to evalaute TandAbs with natural killer cell product of MD Anderson |
2017-01-04 |
| Aptarion Biotech–Noxxon: investment, 201701 Noxxon receives Aptarion shares as part of transfer of preclinical assets to Aptarion |
2017-01-04 |
| Aptarion Biotech–Noxxon: Spiegelmer technology, 201701 acquisition techn + preclinical assets + lab assets from Noxxon for cash + royalties + shares |
2017-01-04 |
| BioControl Systems–Merck (DE): investment, 201701 acquisition €na of BioControl Systems Inc by Merck KGaA |
2017-01-04 |
| InVivo Biotech Services–Bruker Corp: investment, 201701 acquisition €na of InVivo Biotech Services GmbH by Bruker |
2017-01-04 |
| SCiLS GmbH–Bruker Corp: investment, 201701 acquisition €na of SCiLS GmbH by Bruker |
2017-01-04 |
| Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 |
2017-01-04 |
| Laboratoire LCA (MA)–SGS: investment, 201701 acqisition by SGS |
2017-01-03 |
| Bio-ITech–Eppendorf: investment, 2017Q1 acquisition of majority share in Bio-ITech BV by Eppendorf |
2017-01-01 |
| Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund |
2017-01-01 |
| dKK GmbH–Bavaria (govt): science/business park services, 201704– supply serivce dKK GmbH Martinried is new tenant at IZB Martinsried |
2017-01-01 |
| Horizon Discovery–ERS Genomics: CRISPR technology, 201701– license ww non-excl expansion |
2017-01-01 |
| Immunic–Bavaria (govt): science/business park services, 201701– supply service Immunic AG is new tenant at IZB Martinsried |
2017-01-01 |
| Middle Peak Medical–Symetis: investment, before 2017 acquisition by Symetis SA |
2017-01-01 |
| Pionyr Immunotherapeutics–Minapharm: biopharma production, 2017– supply service cell line + process dev + production of therap antibody by ProBioGen |
2017-01-01 |
| Ridgeway Biologicals–Klocke: investment, 201701 acquisition of Ridgeway Biologicals by IDT Biologika |
2017-01-01 |
| SciMab–Bavaria (govt): science/business park services, 201701– supply serivce SciMab GmbH is new tenant at IZB Martinsried |
2017-01-01 |
| Genkyotex–Genticel: investment, 201612–201702 reverse merger with Genkyotex’ owners holding 80% of merged entity |
2016-12-22 |
| PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) |
2016-12-22 |
| C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG |
2016-12-21 |
| Laagrima (MA)–SGS: investment, 201612 acquisition by SGS |
2016-12-21 |
| Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma |
2016-12-20 |
| C-Labs (CH)–SGS: investment, 201612 acquisition of controlling stake by SGS |
2016-12-19 |
| Active Spectrum–Bruker Corp: investment, 201612 acquisition €na of Active Spectrum by Bruker |
2016-12-16 |
| Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED |
2016-12-16 |
| Bluebird Bio–Apceth: contract manufacturing, 201612– collab strategic European manufacturing of Lenti-D + LentiGlobin by Apceth Biopharma GmbH |
2016-12-15 |
| Kohlberg Kravis Roberts–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza |
2016-12-15 |
| Noxxon–Merck (US): cancer immunotherapy, 201612– collab clinical research combi of Keytruda + NOX-A12 in metastatic colorectal + pancreatic cancer |
2016-12-15 |
| Univercells–Gates Foundation: grant, 201612 grant $12m to reduce costs of vaccines for developing countries in collab w Batavia + Natrix |
2016-12-15 |
| Acousia Therapeutics–SEVERAL: investment, 201612 financing round €2.5m led by BIVF + incl KfW + Axxam |
2016-12-14 |
| Amcure–SEVERAL: investment, 201612 financing round Series B €6m led by LBBW Venture Capital GmbH |
2016-12-14 |
| Gilupi–Viroad: investment, 201612 acquisition of remaining shares in Gilupi by Viroad after becoming largest shareholder in 2012 |
2016-12-14 |
| Carpegen–Lifescience Business Consulting: business consulting, 201612 supply portfolio/market analysis for sale of Gyronimo RT-PCR platform to Curetis |
2016-12-13 |
| Carpegen–Osborne Clarke: legal services, 201612 supply legal advisor for sale of Carpegen’s Gyronimo RT-PCR platform to Curetis |
2016-12-13 |
| Carpegen–Systec Elektronik: real-time PCR technology, 201612 collab existent development of Gyronimo platform co-owned by Carpegen + Systec |
2016-12-13 |
| Curetis–Carpegen: real-time PCR technology, 201612 acquisition €5m cash + €2.5m+€9m milestones of Gyronimo platform from Carpegen + Systec |
2016-12-13 |
| Genome Diagnostics–Illumina: DNA sequencing, 201612– collab GenDx non-excl reseller of Illumina porudcts for HLA sequencing in several countries |
2016-12-13 |
| BlueRock Therapeutics–Bayer: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures |
2016-12-12 |
| BlueRock Therapeutics–SEVERAL: investment, 201612– launches with financing round Series A $225m committed by Bayer + Versant Ventures |
2016-12-12 |
| BlueRock Therapeutics–Versant Ventures: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures |
2016-12-12 |
| Curetis–EU (govt): credit, 201612– up to €25m (incl €10m immediately) growth capital loan from EBI to advance Unyvery platform |
2016-12-12 |
| EURE-CART project–EU (govt): grant, 201612c– Horizon 2020 grant €5.9m 4y for clinical research on CART T-cell immunotherapy |
2016-12-12 |
| MolMed–EU (govt): grant, 201612c– Horizon 2020 grant €2m for MolMed for 4y as coordinator of EURE-CART project |
2016-12-12 |
| Biopremier (PT)–SGS: investment, 201612 acquisition of 70% stake by SGS |
2016-12-09 |
| Forge Therapeutics–Evotec: drug discovery services, 201612– collab strategic alliance lead optimisation of LpxC inhibitors by Evotec |
2016-12-09 |
| Numares–Ruth Group: public relations, 201612 service existent US PR + IR by The Ruth Group |
2016-12-08 |
| TCR2 Therapeutics–F2 Ventures: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures |
2016-12-07 |
| TCR2 Therapeutics–MPM Capital: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures |
2016-12-07 |
| TCR2 Therapeutics–SEVERAL: investment, 201612 financing round Series A $44.5m led by MPM Capital + F2 Ventures |
2016-12-07 |
| Roche–Novimmune: therapeutic antibody, 201612– excl license option €na for all rights to NI-0101 for autoimmune diseases to Genentech |
2016-12-06 |
| Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab |
2016-12-05 |
| Bayer–FaunaPhotonics: digital farming technology, 201612– collab developm sensor technology for insect pest monitoring w Bayer CropScience |
2016-12-05 |
| JnJ–AstraZeneca: budenoside, 201612 acquisition $330m of ww rights excl US to Rhinocort Aqua by Cilag GmbH International |
2016-12-05 |
| International Phenome Centre Network–Bruker Corp: NMR technology, 201611– collab Bruker is key partner for NMR technologies + methods + SOPs |
2016-12-02 |
| International Phenome Centre Network–Imperial College London: phenomics, 201611– collab MRC-NIHR UK Phenome Centre is founding partner of IPCN |
2016-12-02 |
| International Phenome Centre Network–Murdoch Univ: phenomics, 201611– collab Separation Science + Metabolomics Lab is founding partner of IPCN |
2016-12-02 |
| Boehringer–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System in Biberach |
2016-12-01 |
| Celgene–Evotec: drug discovery services, 201612–202111 strategic RnD collab $45m upfront using iPSC platform for drugs neurodegenerative diseases |
2016-12-01 |
| Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene |
2016-12-01 |
| Roche–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech |
2016-12-01 |
| Valneva–France (govt): investment, 201612 existent Bpifrance is 2nd largest shareholder owning 9.6% |
2016-12-01 |
| Valneva–Grimaud: investment, 201612 existent Groupe Grimaud is largest shareholder owning 15.6% |
2016-12-01 |
| Valneva–MVM: investment, 201612 private placement €7.5m w 2.9m new shares at €2.6 to MVM plus acqu existing shares results in 7.5% MVM share |
2016-12-01 |
| Boehringer–ACD/Labs: cheminformatics, 201611– supply deployment of ACD/Spectrus platform by Boehringer in Europe + North America |
2016-11-30 |
| Evotec–Merck (DE): target discovery technology, 201611– collab agreements to combine Merck genome editing technologies w Evotec screening (LT) |
2016-11-30 |
| G7 Therapeutics–Sosei: investment, 201611– acquisition 100% for CHF12m in cash of G7 Therapeutics by Heptares |
2016-11-30 |
| Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy |
2016-11-30 |
| AudioCure Pharma–High-Tech Gründerfonds: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors |
2016-11-29 |
| AudioCure Pharma–MED-EL: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors |
2016-11-29 |
| AudioCure Pharma–SEVERAL: investment, 201611 financing round €9m from new investor MED-EL + existing investor HTGF + private investors |
2016-11-29 |
| GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services |
2016-11-29 |
| Jackson Laboratory–Agilent: grant, 201611– Thought Leader Award to Peter Robinson at Jackons Lab for Genomic Medicine for clinical genomics research |
2016-11-28 |
| Menarini–Chugai: cancer drug, 201611– license ww excl for class I PI3K inhibitor PA799 to Berlin-Chemie Menarini |
2016-11-28 |
| Themis Bioscience–SEVERAL: investment, 201611 financing round Series B €10m 2nd + final closing with additional €3m |
2016-11-28 |
| Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug |
2016-11-22 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 13 14 15 ... 54 55 56 
Date![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
